Skip to Content

Illumina Inc

ILMN: XNAS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$279.00ScdxmWxyzwgyd

New Management Team Is Trying to Turn Illumina's Story Around

Business Strategy and Outlook

Illumina aims to transform human health practices through its leadership of genomic sequencing and related applications. The firm provides a broad range of instruments and related consumables to help researchers and clinicians identify and understand genetic variations. The scale of these projects can be wide, such as population genomic initiatives being pursued in many countries, or narrow, such as noninvasive prenatal screening. We believe Illumina will continue to benefit from the rapidly expanding applications of genomic sequencing tools through its own innovation and select acquisitions.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of ILMN so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center